Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 8/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106817 | 0.84 | OPRL1 (0.60) | OPRL1POLBSIGMAR1CCR3KCNA3 | |
| SCHEMBL8986043 | 0.84 | DRD2 (0.60) | OPRL1CCR3DRD2OPRM1 | |
| SCHEMBL10761785 | 0.83 | OPRL1 (0.61) | OPRL1POLBSIGMAR1CCR3KCNA3 | |
| SCHEMBL1309052 | 0.83 | OPRL1 (0.61) | OPRL1POLBSIGMAR1CCR3KCNA3 | |
| SCHEMBL7076751 | 0.83 | DRD2 (0.48) | OPRL1SIGMAR1DRD2OPRM1MAOA | |
| SCHEMBL18026662 | 0.82 | OPRL1 (0.53) | OPRL1POLBSIGMAR1OPRM1OPRD1 | |
| SCHEMBL7104448 | 0.81 | SIGMAR1 (0.65) | OPRL1POLBSIGMAR1CCR3KCNA3 | |
| SCHEMBL16363588 | 0.79 | OPRL1 (0.66) | OPRL1SIGMAR1DRD2OPRM1OPRD1 | |
| SCHEMBL8213555 | 0.77 | OPRL1 (0.67) | OPRL1POLBSIGMAR1CCR3KCNA3 | |
| SCHEMBL11473746 | 0.77 | OPRL1 (0.67) | OPRL1POLBSIGMAR1CCR3KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | claimed |
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | disclosed |
| US-6130234-A | 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists | WARNER-LAMBERT COMPANY (US) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | GRIN3B, OPRM1, GRIN3A | OPRL1 32/4885POLB 546/4885SIGMAR1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.